In recent years, a noticeable shift has emerged in the realm of clinical cancer research, with pharmaceutical companies now playing a dominant role in funding and conducting trials. This transformation is evident in the stark contrast between industry and federal sponsorships. Between 2018 and
In the world of modern medicine, finding innovative, safer, and more effective treatments for cancer remains a relentless pursuit. Researchers from the University of Nottingham have turned their attention to an unassuming yet potent ally in this fight—the parasitic fungus Cordyceps militaris. S
Cancer research has entered a new era with the advent of patient-derived organoids (PDOs). These sophisticated three-dimensional (3D) models, grown from patient cells, have revolutionized our understanding of tumors and their microenvironments. By mimicking the complexity of human tumors, PDOs have
AstraZeneca has recently submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd), targeting accelerated approval for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that possess EGFR mutations. This submission is a significant
Comprehensive Genomic Profiling (CGP) is revolutionizing cancer treatment by enabling early detection and personalized therapy. A recent study published in the Journal of Clinical Oncology - Oncology Practice (JCO-OP) highlights the significant benefits of early CGP testing in improving clinical
Advancements in cancer diagnosis and treatment have significantly improved survival rates, leading to a growing number of young cancer survivors. This demographic shift brings unique challenges as these individuals navigate life post-treatment, facing physical, emotional, and social upheavals. The
